AYTU: Aytu BioPharma, Inc. Stock

by  •  • Comments Off on AYTU: Aytu BioPharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 7.71
Enterprise Value ($M) 3.17
Book Value ($M) 30.77
Book Value / Share 4.99
Price / Book 0.25
NCAV ($M) -22.41
NCAV / Share -3.63
Price / NCAV -0.34

Profitability (mra)
Return on Invested Capital (ROIC) -0.11
Return on Assets (ROA) -0.04
Return on Equity (ROE) -0.17

Liquidity (mrq)
Quick Ratio 0.81
Current Ratio 0.98

Balance Sheet (mrq) ($M)
Current Assets 63.05
Assets 116.23
Liabilities 85.46
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-13 13G/A Stonepine Capital Management, LLC 9.99 10.85
06-18 13D/A Nantahala Capital Management, LLC 18.20 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-09-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-09 5,354 18,310 29.24
2025-05-08 3,657 13,134 27.84
2025-05-07 135 1,797 7.51
2025-05-06 588 3,334 17.64
2025-05-05 5,283 10,274 51.42

(click for more detail)

Similar Companies
ATOS – Atossa Therapeutics, Inc. ATYR – aTyr Pharma, Inc.
AVTX – Avalo Therapeutics, Inc. BCDA – BioCardia, Inc.
BCLI – Brainstorm Cell Therapeutics Inc.


Financial data and stock pages provided by
Fintel.io